Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing Three Single Dose Injections for Knee Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 25-85 years~* BMI \< 40~* Diagnosis of unilateral knee OA~* Radiographic evidence of OA of the target knee (Kellgren-Lawrence grades 2-4)~* Continued OA pain in the target knee despite at least 6 weeks of: physical therapy and at least one of the following: activity modification (such as reducing impact on the knee), weight loss, and a 2 week trial of NSAID / acetaminophen.~* Knee Osteoarthritis Outcomes Score (KOOS)-Pain subscale 20-65~* Working knowledge of English language (to be able to complete all outcome scores)~* Ability to attend all follow-up appointments~Exclusion Criteria:~* 3+ effusion of the target knee (stroke test grading system)~* Prior injection therapy:~  * Steroid injection in target knee in the last 3 months~ * Viscosupplementation in target knee in the last 6 months~ * PRP in the target knee in the last 6 months~ * Cellular treatments in index knee (bone marrow, amniotic suspensions etc) 1 year~ * Participation in any experimental device or drug study within 1 year before screening visit~* Oral or IM steroids in the last 3 months (Inhaled steroids used in the treatment of asthma/allergies are permitted)~* Medical condition that may impact outcomes of procedure including:~  * Systemic inflammatory disorders that impact the joints like rheumatoid arthritis, lupus, etc~ * Undergoing current cancer treatment (other than non-melanoma skin malignancies)~* Taking immunosuppressants~* Previous cartilage repair procedure on the injured cartilage surface (ie, OATS, ACI, MFX) in the last 5 years~* Previous surgery at the target knee within the past 1 year~* Any degree of cognitive impairment~* Symptomatic OA of any other joint in the lower limbs~* Pregnancy, lactating, or intent to become pregnant during treatment period (Female participants will be asked if they are pregnant, lactating, or intend to become pregnant during treatment)~* Gout, Pseudogout (including radiographic evidence of chondrocalcinosis)~* History of infection or current infection at the affected joint~* Smoking (Former smokers\< 1 year from quit date)

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Zilretta (Type: ACTIVE_COMPARATOR): Generic Name: Triamcinolone acetonide Zilretta is an extended-release synthetic corticosteroid indicated as an intra-articular injection for the management ofosteoarthritis pain of the knee.~5mL suspension of 32 mg of triamsinolone administered as a 1 dose parapatellar intra-articular injection.
- Synvisc One (Type: ACTIVE_COMPARATOR): Generic Name: Hylan G-F 20 Synvisc-One combines the three doses of SYNVISC (hylan G-F 20) which consists of hylan A (average molecular weight6,000,000 daltons) and hylan B hydrated gel in a buffered physiological sodium chloride solution, pH 7.2.~Each 10 mL syringe of Synvisc-One combines the three 2-mL doses (16 mg each) of a complete SYNVISC treatment regimen (48 mg). Synvisc-One belongs to a class of drugs called Intra-Articular Agents; Rheumatologics, Other.~10mL of Hylan G-F 20 administered as a 1 dose parapatellar intra-articular injection.
- Monovisc (Type: ACTIVE_COMPARATOR): Generic Name: Hyaluronan The Monovisc™ device is a proprietary high molecular weight hyaluronic acid (HA) viscosupplementation intended for the treatment of pain in patients with moderate osteoarthritis (OA) of the knee who have failed conservative non-pharmacological therapy and simple analgesics. The device is administered by a single injection via the para-patellar approach under sterile conditions.~4mL injection of Hyaluronan administered as a 1 dose parapatellar intra-articular injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).